Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses
Peter Hess
The Transmitter 2023 DOI: 10.53053/nbdr8957 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Reboot Autism Clinical trial Implant |
| Key findings | Decade-old data from a trial of arbaclofen for fragile X syndrome is being revisited, and a new implant-based approach to quelling seizures is being explored. |
Abstract
Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.
Comparable studies
Other narrative reviews on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| The pharmacology of psilocybin | 2002 | Review | |
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Psychedelics, Meditation, and Self-Consciousness | 2018 | Review | |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | 2018 | Review |